Treats partial-onset seizures. ANDA 207300, held by Macleods Pharms. Oxcarbazepine.
As of Nov 16, 2026, ANDA 207300 (Oxcarbazepine), held by Macleods Pharms, was first approved by FDA on Jul 11, 2025, with 0 approved supplements and 0 published complete response letters.
Oxcarbazepine oral suspension, USP is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine oral suspension, USP is indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 11, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxcarbazepine300MG/5ML · suspension;oral | Oxcarbazepine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters